|
1 ngwa (10 Vials)
| Ọnụọgụ: | |
|---|---|
▎ TA1 Ọdịdị
Isi mmalite: PubChem |
Usoro: SDAAVDTSSEITTKDLKEKKEVVEEAEN Ụdị mkpụrụ ndụ: C 129H 215N 33O55 Ibu ibu: 3108.3 g/mol Nọmba CAS: 62304-98-7 PubChem CID: 16130571 Synonyms: Thymalfasin; Zadaxin |
▎ TA1 Nnyocha
Kedu ihe bụ TA1?
TA1 bụ polypeptide nke nwere amino acid 28 mejupụtara. O doro anya na ọ dị na thymus ma na-arụ ọrụ dị oke mkpa na ntozu oke na usoro dị iche iche nke mkpụrụ ndụ T.
Kedu ihe ndabere nyocha nke TA1?
TA1 bụ polypeptide bioactive dịpụrụ adịpụ ma sachaa site na akụkụ nke thymosin 5, nke nwere amino acid 28. Thymus bụ akụkụ dị mkpa nke usoro ahụ ji alụso ọrịa ọgụ, nke na-emepụta ihe dị iche iche na-achịkwa ọrụ mgbochi ọrịa, thymosin bụkwa otu n'ime ha. Site na nyocha miri emi nke ọrụ nke thymus, ndị mmadụ ejirila nwayọọ nwayọọ ghọta na ihe ndị na-arụ ọrụ n'ime ya nwere ike ịba uru maka ọgwụgwọ ọrịa dị iche iche.
Kedu ihe bụ usoro nke TA1?
Immunomodulation:
TA1 bụ ihe mgbanwe nzaghachi ndu nke nwere ike ịgbalite mkpụrụ ndụ dị iche iche na sistemu ahụ ji alụso ọrịa ọgụ. Ọ na-achịkwa ọrụ mgbochi site n'ịkwalite ọdịiche na maturation nke mkpụrụ ndụ T (Sjogren MH, 2004; Mao L, 2023). Kpọmkwem, TA1 nwere ike imetụta thymocytes site n'ịkwalite ọdịiche ha ma ọ bụ gbanwee ha ka ha bụrụ sel T na-arụ ọrụ.
Usoro mgbochi mkpali:
Na ọgwụgwọ COVID-19 oyi baa, TA1 na-eme ka mgbake sitere na oyi baa site na usoro mgbochi mkpali ya. Ọ nwere ike belata nzaghachi mkpali, kwalite mbelata nke COVID-19 ka oyi baa dị ka ahụ ọkụ na ike ọgwụgwụ, mee ka nnabata nke exudate dị mfe, ma mee ka mgbake sitere na oyi baa COVID-19 (Wang Z, 2023).
Kedu ka Thymalfasin si ebute apoptosis nke mkpụrụ ndụ tumo na ọgwụgwọ ọrịa kansa?
Ịkwalite ọrụ nke sel ndị na-alụso ọrịa ọgụ:
Thymalfasin bụ thymopeptide sịntetik nwere ọrụ na-eme ka ahụ ike dị elu. Ọ nwere ike ịkwalite mmetụta igbu mmadụ nke mkpụrụ ndụ na-alụso ọrịa ọgụ na mkpụrụ ndụ tumo, si otú ahụ na-ebute apoptosis nke mkpụrụ ndụ etuto na-apụtaghị ìhè. Dịka ọmụmaatụ, na microenvironment tumor, Thymalfasin nwere ike ịkwalite ọdịiche na maturation nke mkpụrụ ndụ T ma kwalite ọrụ nke mkpụrụ ndụ T. Dị ka akụkụ dị mkpa nke usoro ahụ ji alụso ọrịa ọgụ, mkpụrụ ndụ T nwere ike ịmata ma wakpo mkpụrụ ndụ tumor, na-ebute apoptosis nke mkpụrụ ndụ tumo site na ịhapụ ihe cytotoxic na ụzọ ndị ọzọ.
Na-ahazi nzaghachi mgbochi ọrịa:
Dị ka immunopotentiator, Thymalfasin nwere ike na-ahazi nzaghachi nke dịghịzi ahụ ma mee ka apoptosis nke mkpụrụ ndụ tumo. Ọ nwere ike ịkwalite nzaghachi mgbochi Th1. Mkpụrụ ndụ Th1 na-ezobe cytokines dị ka IFN-γ, nke nwere ike ime ihe na mkpụrụ ndụ tumo ma mee ka apoptosis ha pụta. Tụkwasị na nke ahụ, Thymalfasin nwekwara ike ịhazi ọrụ nke mkpụrụ ndụ ndị ọzọ na-alụso ọrịa ọgụ, dị ka ịkwalite ọrụ nke mkpụrụ ndụ NK. Mkpụrụ ndụ NK nwere ike igbu mkpụrụ ndụ tumor ozugbo ma mee ka apoptosis nke mkpụrụ ndụ tumo site na nzuzo cytokines na ụzọ ndị ọzọ [1].
Imeziwanye mgbochi immunosuppression n'oge ọgwụgwọ mgbochi tumor:
N'oge usoro ọgwụgwọ tumor, ndị ọrịa na-enwetakarị immunosuppression, nke ga-emetụta irè ọgwụgwọ tumor. Thymalfasin nwere ike melite immunosuppression nke a na-emepụta n'oge ọgwụgwọ ọrịa tumor, kwalite ikike nke usoro ahụ ji alụso ọrịa ọgụ ọgụ mkpụrụ ndụ tumo, ma si otú ahụ mee ka apoptosis nke mkpụrụ ndụ tumo. Dịka ọmụmaatụ, n'oge chemotherapy ma ọ bụ redio, usoro ahụ ji alụso ọrịa ọgụ ga-emebi ruo n'ókè ụfọdụ. Thymalfasin nwere ike ịkwalite mgbake na mmụba nke mkpụrụ ndụ na-alụso ọrịa ọgụ, meziwanye ọrụ nke usoro ahụ ji alụso ọrịa ọgụ, ma kwalite mmetụta igbu mmadụ na mkpụrụ ndụ tumo.
Thymosin alpha 1 nwere ọtụtụ ihe omume ndu.
Isi mmalite: PubMed [6]
Kedu ihe bụ ngwa Thymalfasin?
Ọrịa nje virus:
N'ihi mmetụta immunomodulatory ya, TA1 na-ejikarị agwọ ọrịa nje. Dịka ọmụmaatụ, n'oge ọrịa COVID-19, o gosipụtala ezigbo nrụpụta ụlọ ọgwụ na ọgwụgwọ nke oyi oyi COVID-19. Nnyocha na-egosi na TA1 nwere ike igbochi ọganihu nke ọrịa COVID-19 na-emekarị ka ọ bụrụ oyi oyi siri ike site na usoro nchebe dị iche iche na-akwalite mgbochi na mgbochi mkpali [2] . Kpọmkwem, maka ndị ọrịa na-agwọ TA1, ọnụnọ ụlọ ọgwụ na-ebelata nke ukwuu, akụkụ nke enyemaka nke mgbaàmà ndị metụtara oyi oyi (dịka ahụ ọkụ na ike ọgwụgwụ) dị elu karịa nke ndị na-ahụ maka njikwa, na mpaghara nke exudation mkpali nke CT gosipụtara dịkwa ntakịrị karịa nke ndị na-ahụ maka njikwa [2] . Na mgbakwunye, nyocha ihe nlereanya Cox multivariate gosiri na ndị ọrịa ji TA1 na ndị ọrịa na-eto eto nwere nnukwu mgbanwe mgbanwe na-adịghị mma nke COVID-19 antigens [2] . Tα1 (isi ihe dị na TA1) mụbara ọnụ ọgụgụ cell CD4 + T na ndị ọrịa nwere nkwado iku ume oxygen dị ala na ntọala ngwa ngwa karịa ọgwụgwọ ọkọlọtọ, ma nwee ike rụọ ọrụ na ọgwụgwọ nke ndị ọrịa nọ n'ụlọ ọgwụ nwere hypoxemia na lymphopenia nke COVID-19 [3] kpatara..
Ọgwụgwọ ịba ọcha n'anya:
TA1 nwekwara mmetụta ụfọdụ na ọgwụgwọ ịba ọcha n'anya. Enwere ike iji ya mee ihe dị ka monotherapy maka ịba ọcha n'anya B ma ọ bụ na-ejikọta ya na interferon α-2b maka ọgwụgwọ ịba ọcha n'anya C. Kpọmkwem, nchọpụta chọpụtara na n'ịgwọ ọrịa ịba ọcha n'anya B, a na-enyocha irè nke TA1 na ule anọ nke ụlọ ọgwụ metụtara ndị ọrịa 195. N'ime otu n'ime ọmụmụ ihe ahụ, 9 n'ime ndị ọrịa 17 na-agwọta na TA1 nwere ọrịa ịba ọcha n'anya B (HBV) DNA na ọnwa isii, ma e jiri ya tụnyere 10 n'ime ndị ọrịa 16 na-agwọ ọrịa interferon α-2b na 4 n'ime ndị ọrịa 15 na-achịkwa akụkọ ihe mere eme.
Ọgwụgwọ adjuvant: A na-ejikwa TA1 n'ọtụtụ ebe na ọgwụgwọ ọrịa kansa. Maka ndị ọrịa nwere ọrịa cancer akpa ume na-abụghị obere cell (NSCLC) na ọrịa imeju, na ọgwụgwọ adjuvant, TA1 nwere ike imeziwanye ọnụego nlanarị (OS) (Mao L, 2023). Maka ndị ọrịa nwere NSCLC na-enweghị mgbagha na mpaghara, TA1 nwere ike ibelata lymphopenia na oyi baa nke sitere na radiotherapy na chemotherapy, na enwere usoro nke ịkwalite OS [4]..
Na-akwalite mgbochi tumor:
Ihe akaebe gara aga na-egosi na TA1 nwere ike gbanwee M2 polarization nke efferocytosis nke macrophages kpatara site n'ịgbalite axis TLR7/SHIP1, na-eme ka ọ dị irè nke chemotherapy cancer, na-eme ka mgbochi tumor dịkwuo elu site n'ịgbanwe ' etuto oyi' ka ọ bụrụ etuto ọkụ' (Mao L, 202). Tụkwasị na nke ahụ, TA1 nwekwara mmetụta nchebe na mbenata colitis kpatara site na ndị na-eme ihe na-enyocha ihe mgbochi (ICIs) ma nwee ike ịkwalite nrụpụta ụlọ ọgwụ nke ICI [4] . Tα1 dị ka ọgwụgwọ adjuvant mgbe a gbasasịrị ọrịa cancer imeju nwere ike imeziwanye amụma nke ndị ọrịa nwere obere carcinoma hepatocellular. N'ime ọmụmụ ihe na-emeghachi azụ azụ, ndị ọrịa nwere obere carcinoma hepatocellular bụ ndị na-emeju imeju na-ekewa n'ime ìgwè abụọ, otu A (resection + Tα1) na otu B (naanị resection). Mgbe usoro mgbasa ozi nke ọnwa 47.0 gasịrị, 1-, 3-, na 5-afọ n'ozuzu nke lanarị na ọnụ ọgụgụ ndị na-adị ndụ na-adịghachi ndụ nke ndị ọrịa nọ n'ìgwè A dị elu karịa ndị nọ n'ìgwè B. Multivariate analysis gosiri na Tα1 bụ ihe na-emepụta ihe na-emepụta onwe ya maka ọnụ ọgụgụ ndụ zuru ezu na nlọghachi azụ na-enweghị ndụ [5]..
Iweghachi ọrụ mgbochi ọrịa yana nkwalite ọgwụ mgbochi:
Enwere ike iji TA1 na-emeso steeti immunocompromised na malignancies yana dị ka nkwalite nke nzaghachi ọgwụ mgbochi [4, 6] . Ọ nwere ike ịhazi usoro ahụ ji alụso ọrịa ọgụ ma kwalite ọrụ T cell, ma nwee ike ịnweta uru ụlọ ọgwụ maka ọrịa ndị na-adịghị arụ ọrụ ma ọ bụ na-adịghị arụ ọrụ dị ka ọrịa na-adịghị ala ala na ọrịa na-adịghị ala ala, ọrịa cancer, na ọgwụ mgbochi na-enweghị nzaghachi [4] . Nnyocha egosila na na sepsis siri ike, TA1 egosila na ọ na-eweghachi ọrụ mgbochi ma nyere aka belata ọnụ ọgụgụ ndị ọrịa na-anwụ [4]..
Na-egbochi ọrịa COVID-19 na nsogbu dị n'ime ndị ọrịa na-eme dialysis gbasara akụrụ:
A na-ahụta ndị ọrịa nwere ọrịa akụrụ ngwụcha (ESRD) na-anata hemodialysis (HD) dị ka ndị nwere ike ibute ọrịa SARS-CoV2 n'ihi ihe ndị dị ka ịka nká, ibu nsogbu, iji ọgwụ eme ihe, yana mkpa ịga ụlọ ọgwụ dialysis ugboro ugboro. Nnyocha mbụ egosila na TA1, dị ka onye na-akwado ọgwụ mgbochi influenza, nwere ike ịkwalite nzaghachi mgbochi nke ndị agadi (gụnyere ndị ọrịa HD) na ọgwụ mgbochi influenza ma belata ọrịa influenza. N'ụbọchị mbụ nke ọrịa COVID-19, ndị nchọpụta kwuru na inye ndị ọrịa TA1 na HD nwere ike ibelata ọnọdụ na ịdị njọ nke ọrịa COVID-19. Dị ka nke July 1, 2022, 254 ESRD / HD ndị ọrịa sitere na ụlọ ọrụ dialysis ise dị na Kansas City, Missouri gụnyere na ọmụmụ ihe, nke ndị ọrịa 194 na-ekewa n'ụzọ na-enweghị usoro n'ime otu A (ntụtụ subcutaneous nke 1.6mg TA1 ugboro abụọ n'izu maka izu 8) na otu B (òtù njikwa, na-enwetaghị TA1) [7].
N'ikpeazụ, dị ka polypeptide nwere ọrụ immunomodulatory pụrụ iche, TA1 egosila ngwa nwere ike n'ọtụtụ akụkụ na ngalaba ahụike. N'ịgwọ ọrịa nje, ọ na-enwe mmetụta dị ukwuu na ọrịa ndị dị ka ịba ọcha n'anya B na COVID-19. Ọ bụghị naanị na ọ ga-eme ka nkwụsị nke mgbaàmà dịkwuo ngwa ngwa ma belata mbufụt kamakwa igbochi ọganihu nke ọrịa ahụ ma melite ọnụego mgbake nke ndị ọrịa. N'ihe gbasara ọgwụgwọ tumor, ọ nwere ike ime ka apoptosis nke mkpụrụ ndụ tumo site n'ọtụtụ ụzọ, welie mmetụta igbu egbu nke mkpụrụ ndụ na-alụso ọrịa ọgụ na mkpụrụ ndụ tumo, ma melite ọnọdụ immunosuppressive, na-egosi arụmọrụ dị mma na ọgwụgwọ ọrịa cancer dị iche iche dị ka ọrịa cancer akpa ume na ọrịa imeju.
Banyere Onye dere ya
Ihe niile a kpọtụrụ aha n'elu bụ Cocer Peptides na-enyocha, dezie ma chịkọta ya.
Onye ode akwụkwọ akụkọ sayensị
Wang Z bụ onye nyocha nwere mmụta mmụta dị iche iche yana ahụmịhe mmekọrịta dị ukwuu n'ofe ụlọ ọrụ dị iche iche. Ihe gbasara nyocha ha gbasara mpaghara interdisciplinary dị ka Engineering, Spectroscopy, Chemistry, Dentistry, Oral Surgery & Medicine, na Physics. Ejikọtala Wang Z na ụlọ ọrụ na mahadum a ma ama, gụnyere Mahadum China Academy of Sciences (CAS), Mahadum Yunnan, Mahadum Peking, Mahadum Ugbo Hunan, Mahadum Shanghai Jiao Tong, na ọtụtụ ndị ọzọ. Ọrụ ha na-egosipụta nlebara anya siri ike na mmepụta ọhụrụ na imekọ ihe ọnụ, karịsịa na mpaghara metụtara ọkụ ụlọ ọrụ optoelectronic engineering, ngwa ahụike, na sayensị ihe dị elu. Site na mmekorita ya na ulo oru dika Jiangsu Provincial Research Center maka Light Industrial Optoelectronic Engineering & Technology na Air Force Military Medical University, Wang Z enyela aka na mmepe nke usoro ihe omuma na ngwa bara uru n'ubi ha. Edepụtara Wang Z n'akwụkwọ ntụaka [2].
